LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.7800
-0.0200 (-2.50%)
As of 3:29PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.8000
Open0.8600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7511 - 0.8600
52 Week Range0.7500 - 2.2400
Volume61,864
Avg. Volume85,056
Market Cap61.337M
Beta (3Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.35
Trade prices are not sourced from all markets
  • CNW Group2 days ago

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • ACCESSWIRE6 days ago

    Lexaria Bioscience Enters CBD License Agreement with Universal Hemp

    KELOWNA, BC / ACCESSWIRE / July 11, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp., to provide Lexaria’s patented DehydraTECHTM technology to Universal Hemp LLC, a B2B manufacturing company of high-performing hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries, for utilization into many CBD-based food ingredients to be produced and sold across the USA immediately, and in Canada when regulations permit. Competitive financial details including royalty rates remain confidential and undisclosed although the companies have agreed to disclose minimum payments over the life of the agreement of US$3,750,000.

  • ACCESSWIRE7 days ago

    Lexaria Bioscience Enters CBD Beverage License Agreement with Nic’s Beverages

    KELOWNA, BC / ACCESSWIRE / July 10, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria’s patented DehydraTECHTM technology to Nic’s Beverages L.L.C. for use in CBD-based beverages to be produced and sold throughout the United States.

  • PR Newswire8 days ago

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • ACCESSWIRE26 days ago

    Lexaria Announces 2019 Annual and Special Meeting Results

    KELOWNA, BC / ACCESSWIRE / June 21, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2019 Annual and Special Meeting ...

  • GlobeNewswirelast month

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

    NEW YORK, June 13, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled,.

  • Newsfilelast month

    DehydraTECH: The Cynosure of Efficient CBD Delivery -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 13, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).Scientists use words like "bioavailability," "pharmacokinetics" and "targeted" in describing keys to efficiently treating disease and conditions. To the patient, it is just swallowing a pill, but there are years of research that goes ...

  • GlobeNewswirelast month

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements

    NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • ACCESSWIRElast month

    Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents

    New Enhanced DehydraTECH™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations. KELOWNA, BC / ACCESSWIRE / June 4, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECH™ delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. The Company has filed new patent applications related to the recent innovations.

  • GlobeNewswire2 months ago

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

    Consider what [Lexaria BioScience Corp.’s DehydraTECH] technology could mean for the CBD edibles space. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • GlobeNewswire2 months ago

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Discussing Disruptive Potential of CBD Delivery Technology

    NEW YORK, May 30, 2019 -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire.

  • ACCESSWIRE2 months ago

    Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

    KELOWNA, BC / ACCESSWIRE / May 28, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria's DehydraTECHTM delivery technology with generic nanotech techniques delivers 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. On March 20, 2019, Lexaria announced it was beginning a series of animal studies with multiple objectives that included developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier ("BBB") to enter brain tissue.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience and Nuka Enterprises' 1906 Expand Cannabis Product Relationship

    KELOWNA, BC / ACCESSWIRE / May 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), an innovator in drug delivery platforms, today announced the most reliable fast acting edibles on the market will now be available across the country through a major expansion in operations by Nuka Enterprises LLC, ("Nuka") maker of 1906 cannabis edibles for high functioning adults. Last year, Nuka acquired contractual options to expand its use of DehydraTECHTM technology. Exercising some of those options, Nuka plans to expand operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020.

  • ACCESSWIRE2 months ago

    Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

    Lexaria's DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles. KELOWNA, BC / ACCESSWIRE / May 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company

    KELOWNA, BC / ACCESSWIRE / May 7, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria's patented DehydraTECHTM technology to a private Nevada-based company for its utilization in certain CBD-based beverages to be produced and sold across the USA. Lexaria has developed methods of combining nano-emulsion technology with its proprietary DehydraTECH processes to create beverages with market-leading aesthetic and performance characteristics. Lexaria continues to experience strong demand in North American markets for use of its technology for beverage applications.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Expands Advisory Board

    KELOWNA, BC / ACCESSWIRE / April 25, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce new appointments to its Scientific Advisory Board, each of whom will contribute advice and recommendations and support related to the Company's scientific research and product development. Lexaria is honored to have the opportunity of working with each of them. Dr. Dwayne Godwin is Dean of the Graduate School and Professor in the Departments of Neurobiology and Anatomy and the Institute for Regenerative Medicine at Wake Forest University.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Announces Beverage License Agreement with California-Based Cannabis Company

    KELOWNA, BC / ACCESSWIRE / April 24, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria CanPharm ULC, to provide Lexaria's patented DehydraTECHTM technology to a private California-based cannabis company for its utilization in certain cannabis-based beverages to be produced and sold in the states of California and Nevada. Lexaria has developed methods of combining nano-emulsion technology with its proprietary DehydraTECH processes to create beverages with market-leading aesthetic and performance characteristics. Lexaria is currently experiencing unprecedented demand in several North American markets for use of its technology for beverage applications.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services

    KELOWNA, BC / ACCESSWIRE / April 15, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) ("Lexaria" or the "Company") announces it has retained Oak Hill Financial Inc. ("OakHill") to provide investor relations services to the Company in compliance with regulatory guidelines. Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that are utilized to gain exposure and recognition in the capital markets. Oak Hill provides asset management, capital market, and investor relations services.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options

    KELOWNA, BC / ACCESSWIRE / April 9, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated renewal management contracts with Chief Executive Officer Chris Bunka and President John Docherty. The new contracts are for 3-year terms and ensure that the Company can seamlessly pursue its business goals and create shareholder value while providing management continuity during this period of corporate growth. Lexaria will always strive to provide excellence in management which is always aligned with the interests of shareholders.

  • Newsfile4 months ago

    BTV Highlights 5 Companies Spearheading Innovation

    Vancouver, British Columbia--(Newsfile Corp. - March 28, 2019) - On national TV Sat Mar. 30 & Sun Mar. 31, 2019 - BTV- Business Television visits five inventive small cap companies leading advancements in their sectors. Full EpisodeNexTech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) - BTV shares how this company's AR - Augmented Reality technology is disrupting the world of e-commerce . See Feature High Tide Inc. (CSE: HITI) - BTV ...

  • Newsfile4 months ago

    Lexaria Bioscience Corp., Ingesting Instead of Inhaling Could Save 60,000 Lives a Year, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2019) - Chris Bunka, CEO of Lexaria Bioscience shares the company's unique opportunity to make ingesting any number of drugs and molecules healthier with their DehydraTECH technology.If you cannot view the video above, please visit:https://www.b-tv.com/lexaria-bioscience-ceo-clip-90sec/ Lexaria Bioscience Corp. is being featured on BNN Bloomberg on Mar. 23 - Mar. 24, 2019, throughout the day and evenings.Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)www.lexariabioscience.com About CEO ...

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Begins Largest Cannabinoid R&D Program in its History

    KELOWNA, BC / ACCESSWIRE / March 20, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. This new program is comprised of 11 separate animal studies, each of which is comparable in scope to individual animal studies conducted by the Company during 2018. Lexaria began its 2019 in vivo study design six months ago and laboratory test articles have all been produced and exceed all required quality control thresholds.

  • ACCESSWIRE5 months ago

    Lexaria Bioscience Comments on FDA Statement on Novel Nicotine Replacement Therapies

    KELOWNA, BC / ACCESSWIRE / February 26, 2019 / Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, comments on the February 21, 2019 U.S. Food & Drug Administration (''FDA") statement outlining the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, and the FDA draft guidance issued: ''Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products''. Lexaria has recently partnered with a world-leading tobacco company that has licensed the Company's DehydraTECHTM technology to develop novel oral nicotine products utilizing Lexaria's technology that could harmonize with the evolving FDA strategy.